NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson’s Disease

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1559-1182
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson’s Disease ; day:8 ; month:10 ; year:2021 ; pages:1-16
Molecular neurobiology ; (8.10.2021), 1-16

Creator
Anantha, Jayanth
Goulding, Susan R.
Tuboly, Eszter
O’Mahony, Adam G.
Moloney, Gerard M.
Lomansey, Gareth
McCarthy, Cathal M.
Collins, Louise M.
Sullivan, Aideen M.
O’Keeffe, Gerard W.
Contributor
SpringerLink (Online service)

DOI
10.1007/s12035-021-02569-6
URN
urn:nbn:de:101:1-2021122505551889082850
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Anantha, Jayanth
  • Goulding, Susan R.
  • Tuboly, Eszter
  • O’Mahony, Adam G.
  • Moloney, Gerard M.
  • Lomansey, Gareth
  • McCarthy, Cathal M.
  • Collins, Louise M.
  • Sullivan, Aideen M.
  • O’Keeffe, Gerard W.
  • SpringerLink (Online service)

Other Objects (12)

LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models

LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?

Crystallizing the Parkinson’s disease protein LRRK2 under microgravity conditions

Crystallizing the Parkinson’s disease protein LRRK2 under microgravity conditions

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition

Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons

Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons

Models of α-synuclein aggregation in Parkinson’s disease

Models of α-synuclein aggregation in Parkinson’s disease

Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubules

Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubules

Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance

Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance

A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2

A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2

Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease

Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Related objects